IL6 and COVID-19: A pooled analysis of observational studies found that COVID-19 patients with diabetes had significantly higher levels of inflammatory and hypercoagulability markers such as interleukin-6 (IL-6) and fibrinogen than non-diabetic COVID-19 patients (36), reflecting cytokine storm and intravascular coagulation that may eventually lead to disease progression in diabetic COVID-19 patients.